Patent Application
20190293662
Stroke is a leading cause of death worldwide and can be defined as the rapidly developing loss of brain function(s) due to interruption in the blood supply to the brain. According to the World Health Organisation, 15 million people per annum suffer stroke world-wide with 5 million dying and a further 5 million being permanently disabled. An ischaemic stroke (IS) results in the blood supply to the brain being decreased resulting in brain damage and occurs when a blood vessel becomes blocked, usually via a blood clot. This clot may form locally at an atherosclerotic plaque (thrombotic stroke) or alternatively may occur due to a travelling particle or debris that has originated from elsewhere in the bloodstream (embolic stroke). The transient ischaemic attack (TIA) occurs when blood supply to the brain is temporarily decreased. A TIA is diagnosed if symptoms are quickly resolved (within 24 hours with the individual returning to normal health. Haemorrhagic stroke (HS) is the accumulation of blood within the skull vault and can be divided into its two main sub-types, intracerebral haemorrhage (ICH) in which blood leaks into brain tissue, and subarachnoid haemorrhage (SAH) in which blood escapes to the subarachnoid space. A haemorrhagic stroke occurs when a weakened blood vessel ruptures. The stroke-related condition in which an individual presenting with IS transforms at a later time point to HS, is termed ‘Haemorrhagic transformation’ (HT). Ischaemic stroke accounts for approximately 85 percent of all stroke cases and haemorrhagic stroke 15 percent. The 30 day fatality rate for IS is 8-12% and HS is 37-38%. To minimise neurological damage and death following stroke it is crucial that stroke patients are rapidly and accurately diagnosed so that appropriate treatment can be administered. For example, to breakdown clots anti-thrombolytic therapy such as tissue plasminogen activator (tPA) can be administered. However, such therapy is only warranted in IS and is detrimental in HS; the nature of TIA does not require such therapy and blood thinners such as warfarin and aspirin are prescribed in such cases. HT can occur as part of the natural evolution of IS or as a result of anticoagulant or thrombolytic therapy in the acute phase of IS. This poses a serious problem to both the stroke-affected individual and the clinician with respect to decisions on anti-thrombolytic and anti-coagulative therapy use. Therefore, patients admitted to a clinic with stroke-like symptoms present the clinician with a highly complex differential diagnosis task. A clinician who upon confronting a patient suspects stroke must delineate the various stroke-like conditions—stroke mimics (hypoglycemia, drug overdose, migraine, seizures, hyponatremia, loss of consciousness, intracranial tumours, subdural hematoma, hypertensive encephalopathy, encephalitis/meningitis), TIA, IS and strokes that transform into haemorrhagic stroke, and a wrong diagnosis could have fatal consequences. At present if stroke is suspected, physical symptoms are evaluated and a CT scan is usually performed. A CT scan has good sensitivity for identifying HS patients (approximately 90% sensitivity) but has poor sensitivity for the detection of IS. The detection of stroke-related biomolecules (biomarkers) in biological fluids are a potential supportive means of stroke diagnosis. Biomarkers have the potential to expedite and increase the accuracy of stroke diagnosis and various candidate biomarkers have been proposed for diagnosis of stroke. Speed of diagnosis of stroke is especially critical to ensure the best possible outcome for the patient as it enables early treatment. Biomarker measurement using a patient biological sample is more expeditious than implementing a brain scan as well as being technically more simplistic and economical. Glial fibrillary acidic protein (GFAP) is a ˜50 kDa (kDa=kilodaltons) structural protein found predominantly in the brain. It is essentially undetected in healthy patient systemic serum but is released in increasing amounts during HS (EP1668370B1—intracerebral stroke, WO2005/05029088). The utility of GFAP as a biomarker of HS is becoming increasingly recognised but there is always a need for further stroke biomarkers, especially those which provide greater sensitivity and greater accuracy in diagnosing and predicting HS and which support improvements in the differential diagnosis of stroke.
Described are methods of supporting the diagnosis of stroke events in patients using derivatives of GFAP. It has been unexpectedly found that GFAP derivatives make up a substantial proportion of total GFAP protein in samples taken from individuals undergoing a stroke event, and their detection and measurement enables improved assays for the diagnosis and prognosis of stroke. GFAP derivatives are GFAP fragments or species, with or without post translational modification (PTM), derived from native GFAP (parent GFAP). By detecting and measuring total GFAP, GFAP derivatives plus native GFAP, a more sensitive assay results. The invention further describes antibody-based detection methods which through epitopic targeting of amino acid sequences common and/or unique to the various GFAP species, enables assays for improved stroke prediction and diagnosis. These methods can be used independently or can be combined with brain scanning in patients displaying stroke symptoms to predict, diagnose and discriminate fatal ischaemic stroke (IS fatal), haemorrhagic transformation (HT) and haemorrhagic stroke (HS), thus enabling timely and accurate diagnoses, patient treatment prioritisation and more efficient patient management. Also described are antibodies which target areas of the various species of GFAP, peptide domains of GFAP derivatives or native GFAP which incorporate the epitopes bound by the antibodies of the invention that enable the methods of the invention.
During a routine clinical study assessing the utility of native GFAP as a biomarker for haemorrhagic stroke it has been surprisingly found that GFAP derivatives of molecular weight less than native GFAP without PTM represent a major component of total GFAP present in stroke patient samples. The amount of these GFAP derivatives is higher in HS patients, HT patients and fatal IS patients compared to control values. It was also found that further GFAP derivatives, namely native GFAP with post translational modifications and/or GFAP derivatives with a molecular weight of greater than native GFAP without PTM, were also present in the cerebrospinal fluid (CSF) of stroke patients. This enables the use of GFAP derivatives in a clinical or point of care setting as biomarkers of various stroke conditions to inform and support the clinical decision-making process. These various stroke conditions include HS (intracerebral haemorrhage and/or subarachnoid haemorrhage), HT and IS fatal. The use of these GFAP species enables an assay of increased diagnostic power. The assay is more accurate as it avoids categorising samples as devoid of GFAP when GFAP is present (see
‘Native GFAP’ means, unless otherwise stated, one or more of the three characterised GFAP full-length isoforms listed in the Uniprot database, GFAP isoform 1 of Uniprot number P14136-1 synonym GFAP alpha, GFAP isoform 2 of Uniprot number P14136-2 synonym GFAP delta, GFAP isoform 3 of Uniprot number P14136-3 synonym GFAP epsilon, each with or without PTM. GFAP isoform 1 has a mass of 49,880 Da, GFAP isoform 2 has a mass of 50,289 Da, GFAP isoform 3 has a mass of 49,508 Da. Herein a compound may be referred to by i. Uniprot number ii. chemical structure iii. chemical name; in the event of conflict the order of priority for compound identification is i.>ii>iii.
‘GFAP derivative(s)’ means one or more individual GFAP species with or without PTM of molecular weight less than native GFAP without PTM i.e. one or more GFAP species of a molecular weight of less than about 49 kDa (see definition of ‘native GFAP’ for the three reference native GFAP species and their molecular weights) e.g. a GFAP fragment derived from native GFAP that has been enzymatically digested, and/or one or more individual GFAP species with post translational modification of molecular weight greater than native GFAP without PTM i.e. of a molecular weight of greater than about 51 kDa e.g. a hyperglycosylated GFAP fragment of a molecular weight which exceeds about 51 kDa; the definition ‘GFAP derivative(s)’ excludes native GFAP with PTM.
‘Total GFAP’ means native GFAP and GFAP derivatives.
‘GFAP species’ means any GFAP-based protein including all native GFAP isoforms with and without PTM and other GFAP isoforms such as GFAP beta, GFAP kappa, GFAP gamma, GFAPAEx6, GFAPA135, GFAPA164 and GFAPAEx7 (see Moeton et al 2016), GFAP multimers (dimers, tetramers etc based on any of the various isoforms) and their fragments with or without PTM, and GFAP derivatives with or without PTM.
‘IS fatal’ means individuals diagnosed with ischaemic stroke who subsequently die.
‘Pernicious stroke’ means a type of stroke in which the individual has been subject to or is undergoing a potentially life-threatening stroke event. Pernicious stroke can be HS, HT or IS fatal.
‘Haemorrhagic stroke’ includes both intracerebral stroke and subarachnoid stroke unless otherwise stated.
The invention describes a method of diagnosing or supporting the diagnosis of stroke in a subject comprising taking a sample from the subject and measuring the amount of GFAP derivatives present in the sample, the GFAP derivatives being of molecular weight less than native GFAP without PTM, in which an amount of GFAP derivatives in the sample which is greater than the amount of a GFAP control is indicative of stroke—reference to GFAP derivatives includes instances where there exist in a sample i) only GFAP derivatives with PTM ii) only GFAP derivatives without PTM and iii) a mixture of GFAP derivatives, some with and some without PTM. In a preferred embodiment, the GFAP derivative or derivatives of molecular weight less than native GFAP without PTM has or have a molecular weight of about 35-49 kDa, 35-42 kDa, −49 kDa or 35-39 kDa; Preferably, the identified stroke is one or more of haemorrhagic stroke, haemorrhagic transformation and fatal ischaemic stroke. In a preferred embodiment the method comprises: 24 hours from admission or symptom onset measuring the amount of GFAP derivatives, in which GFAP derivatives are of molecular weight less than native GFAP without PTM, in a biological sample taken from the patient and subjecting the patient to a brain scan and, if the GFAP derivatives value is normal and the brain scan negative for haemorrhagic stroke, at ≥24 hours from admission or symptom onset taking a further sample from the patient and measuring the amount of the GFAP derivatives, in which i) a high GFAP derivatives protein level and a brain scan positive for haemorrhagic stroke ≤24 hours from admission or symptom onset indicates haemorrhagic stroke ii) a high GFAP derivatives protein level and a brain scan negative for haemorrhagic stroke ≤24 hours from admission or symptom onset indicates fatal ischaemic stroke iii) a normal GFAP derivatives protein level and brain scan negative for haemorrhagic stroke on admission and a high total GFAP or GFAP derivatives protein level ≥24 hours from admission or symptom onset indicates haemorrhagic transformation. Preferably, samples are taken from a subject ≤6 hours from subject admission or symptom onset. Preferably, the second glial fibrillary acidic protein measurement is taken at 24-96 hours from admission or from symptom onset. Other possible time points for taking a subject sample is at ≤12 hours, ≤8 hours or ≤4 hours from subject admission or symptom onset. Reference to an ‘amount’ of one or more GFAP species is replaceable by other suitable quantifying terms such as ‘concentration’, ‘level’ etc. In all of the methods of the invention it is preferable that the time of symptom onset is the defining reference point. However, circumstances may not allow this due to the subject's condition or lack of third party verification, in which case admission time (which can also include medic arrival at the scene) is used. The sample to be analysed in the methods of the invention can be any suitable biological sample such as blood, serum, plasma, urine, tissue, saliva; the biological sample is preferably a blood sample, a serum sample or a plasma sample. Native GFAP can also be measured in conjunction with GFAP derivatives. In variations of the described method of the invention and in further embodiments of the described method of the invention of diagnosing or supporting the diagnosis of stroke in a subject i) native GFAP and GFAP derivatives of molecular weight less than native GFAP without PTM present in the sample are measured, in which an amount measured which is greater than the amount of a GFAP control is indicative of stroke ii) GFAP derivatives of molecular weight less than native GFAP without PTM and GFAP derivatives of molecular weight greater than native GFAP without PTM present in the sample are measured, in which an amount measured which is greater than the amount of a GFAP control is indicative of stroke iii) GFAP derivatives of molecular weight greater than native GFAP without PTM present in the sample are measured, in which an amount measured which is greater than the amount of a GFAP control is indicative of stroke iv) native GFAP and GFAP derivatives of molecular weight greater than native GFAP without PTM present in the sample are measured, in which an amount measured which is greater than the amount of a GFAP control is indicative of stroke v) native GFAP and all GFAP derivatives present in the sample are measured (i.e. total GFAP) in which an amount measured which is greater than the amount of a GFAP control is indicative of stroke. Preferably, the identified stroke is one or more of haemorrhagic stroke, haemorrhagic transformation and fatal ischaemic stroke. An immuno-based (i.e. antibody-based) technique is the preferred analytical technique, and can be, for example a biochip array technology (BAT) based sandwich or competitive immunoassay format or a lateral flow point of care (POC) format. For the preferred sandwich immunoassay format, two or more antibodies of differing specificity can be used as capture antibodies for the native GFAP and the GFAP derivatives of molecular weight less or more than native GFAP without PTM, together with either a single detector antibody detecting a single epitope common to total GFAP species, or with two or more detector antibodies of differing epitope specificity. However, in a preferred format, a single capture antibody specific to an epitope common to the various GFAP species, and a single detector antibody specific to a different epitope common to the various GFAP species, are used e.g. the antibodies of Kit 2.
Preferably, the method comprises: ≤24 hours from admission or symptom onset measuring the amount of total GFAP in a biological sample taken from the patient and subjecting the patient to a brain scan and, if the total GFAP value is normal and the brain scan negative for haemorrhagic stroke, at ≤24 hours from admission or symptom onset taking a further sample from the patient and measuring the amount of total GFAP in which i) a high total GFAP protein level and a brain scan positive for haemorrhagic stroke ≤24 hours from admission or symptom onset indicates haemorrhagic stroke ii) a high total GFAP protein level and a brain scan negative for haemorrhagic stroke ≤24 hours from admission or symptom onset indicates fatal ischaemic stroke iii) a normal total GFAP protein level and brain scan negative for haemorrhagic stroke on admission and a high total GFAP protein level ≥24 hours from admission or symptom onset indicates haemorrhagic transformation.
Preferably, samples are taken from a subject 6 hours from subject admission or symptom onset. Other possible time points for taking a subject sample is at ≤12 hours, 8 hours or 4 hours from subject admission or symptom onset. Preferably, the second glial fibrillary acidic protein measurement is taken at 24-96 hours from admission or from symptom onset. In each of the previous methods a measured GFAP concentration greater than a GFAP control value is indicative of haemorrhagic stroke, haemorrhagic transformation or fatal ischaemic stroke; preferably, the level of GFAP in the stroke condition is ≥1.1 times, ≥1.2 times, ≥1.5 times ≥2 times, 3 times, or ≥4 times than the control value. These values reflect the fact that GFAP is at very low or undetectable levels in control (‘normal’) samples. Thus the methods of the invention incorporating measurement of GFAP derivatives, can be used in the diagnosis of HS, HT and IS fatal. The methods of the invention can incorporate any suitable antibodies but it is preferable that an antibody which binds to an epitope of a GFAP species within the sequence ETRASERAEMME is incorporated in the methods. Preferably, the epitope comprises a least one amino acid from the sequence SERA within ETRASERAEMME. When the immunoanalytical method is a standard sandwich immunoassay, the ETRASERAEMME binding antibody can be the detector or capture antibody. It is preferably the capture antibody. The capture antibody of the immunoassay can be in solution, in solution bound to a solid-state device such as a bead, microparticle or magnetic particle or adsorbed or chemically attached to a substrate such as a biochip. A biochip is a planar substrate that may be, for example, mineral or polymer based, e.g. glass or plastic, but is preferably ceramic. The solid-state devices used are optionally adapted by being partially or completed covered by a material which promotes an improved assay e.g. a hydrophobic composition. The preferred substrate is a ceramic biochip optionally completely or partially covered with a hydrophobic composition. Hydrophobic compositions, well known in the art, can help minimise or prevent non-specific binding, optimise antibody-containing droplet characteristics when added to the solid-state device, mitigate signal bleeding thus improving detection and quantification. The immunoanalytical method can incorporate a further antibody. For example, the preferred sandwich format includes a further antibody which binds to an epitope which is either common to GFAP derivatives or common to total GFAP species, the epitope bound by the further antibody differing from the epitope bound by the first antibody. The epitope specificity of each of the two antibodies of the immunoassay are sufficiently different that one antibody does not impede or interfere with the binding of the other antibody to its epitope and vice-versa, and that the integrity of the immunoassay in detecting and quantifying GFAP derivatives and/or total GFAP is not compromised. It is preferred that for all immunoanalytical methods used for the diagnosis of stroke that the further antibody binds to an epitope of a GFAP species incorporated in the sequence ERKIESLEEEIR. The GFAP control level as used in the described methods of the invention is one that has been measured in a healthy patient or a healthy population of patients, or has been derived from a population of patients categorised as one or more of TIA, stroke mimic or ischaemic stroke. A ‘control’, unless otherwise qualified, can be native GFAP, a GFAP derivative or any other GFAP species including other GFAP isoforms and their derivatives and GFAP dimers and oligomers and their derivatives, or a mixture of two or more GFAP species that has been measured in a healthy patient or a healthy population of patients or has been derived from a population of patients categorised as one or more of TIA, stroke mimic or ischaemic stroke (the control population); ischaemic stroke patient data can be used as a control if, as shown by current study, GFAP levels do not increase in such patients. The invention further describes the use of GFAP derivatives and native GFAP as markers of stroke. The GFAP derivatives can be GFAP derivatives of molecular weight less than native GFAP without PTM and GFAP derivatives of molecular weight more than native GFAP without PTM (i.e. GFAP fragments with substantial PTM). Preferably GFAP derivatives of molecular weight less than native GFAP with or without PTM are used. The GFAP derivatives are used to support the diagnosis or diagnose haemorrhagic stroke, haemorrhagic transformation and fatal ischaemic stroke. In a further embodiment, the use is effected in conjunction with a brain scan. Brain scan includes computerised tomography (CAT scan), X-ray, magnetic resonance imaging (MRI), ultrasound or any other machine-based (medical device) scan in which the interaction of the brain with wave or particle output from a medical device enables an abnormal brain event to be highlighted, an abnormal brain event being one which potentially injurious to the brain. The uses described are especially applicable to GFAP derivatives incorporating the sequence ETRASERAEMME. The invention also describes an antibody which binds to an epitope of a GFAP species incorporated in the sequence ETRASERAEMME. The epitope bound by the antibody can be two, three, four, five, six, seven or more contiguous amino acid residues. Experimental data show that the two peptide sequences which overlap the sequence ETRASERAEMME, namely sequences GALNAGFKETRA and EMMELNDRFASY, do not bind to the antibody which suggests that one or more of the central, non-overlapping residues of ETRASERAEMME, namely SERA, likely comprise the epitope. Hence in a further embodiment, the invention describes an antibody in which the epitope comprises a least one amino acid from the sequence SERA of ETRASERAEMME. The GFAP species bound by the antibody is preferably a GFAP derivative of molecular weight less than native GFAP with or without PTM and/or native GFAP with PTM. The antibody can bind a GFAP derivative corresponding to the lowest molecular weight GFAP species in the Calbiochem standard which implies that the GF9 and GF10 antibodies bind to a GFAP derivative of molecular weight of about 44 kDa. (see
The invention describes the use of GFAP derivatives as markers of stroke, especially haemorrhagic stroke, haemorrhagic transformation or fatal ischaemic stroke; the GFAP derivative can be of any molecular weight less than native GFAP without PTM and can be of about 35 kDa, 36 kDa, 37 kDa, 38 kDa, 39 kDa, 40 kDa, 41 kDa, 42 kDa, 43 kDa, 44 kDa, 45 kDa, 46 kDa, 47 kDa, 48 kDa and 49 kDa. Protein gels are a standard technique used in protein separation and assignment of approximate molecular weights and the term ‘about’ reflects this. The Calbiochem product number 344596 is a GFAP standard purified from human brain having a molecular weight between 43 and 49 kDa (datasheet). Reference to the Calbiochem standard (Lane A) of the gels of
Preferably the GFAP derivative or derivatives bind to an antibody, the antibody binding an epitope within the sequence ETRASERAEMME of the GFAP derivative(s), preferably to at least one amino acid within the sequence SERA of the GFAP derivative. The antibody is preferably GF9. As used herein, the term ‘ischaemic stroke (IS)’ refers to the type of stroke that occurs when blood supply to the brain is decreased, resulting in brain damage. An ischaemic stroke occurs when a blood vessel becomes blocked, usually via a blood clot. This clot may form locally at an atherosclerotic plaque (thrombotic stroke) or alternatively may occur due to a travelling particle or debris that has originated from elsewhere in the bloodstream (embolic stroke). The term ‘transient ischaemic attack (TIA)’ refers to a ‘mini stroke’ that occurs when blood supply to the brain is temporarily decreased. A TIA is diagnosed if symptoms are quickly resolved (within 24 hours with the individual returning to normal health). The term ‘stroke mimic’ applies to non-stroke conditions that produce one or more symptoms associated with stroke and which leads to the individual's condition initially categorised as possible stroke. The term ‘haemorrhagic stroke (HS)’ occurs when blood accumulates within the skull vault, usually when a weakened blood vessel ruptures. Haemorrhagic stroke can be classified into two major sub-types: intracerebral (within the brain tissue); and subarachnoid (around the surface of the brain and under its protective layer). Haemorrhagic transformation (HT) or a haemorrhagic transformer describes an individual initially diagnosed as ischaemic stroke who at a later point develops haemorrhagic stroke (see Jickling 2014 for a review of HT). References herein to ‘a patient who has suffered or is suffering a stroke’ include a patient who has been diagnosed as currently suffering from a stroke or who is or has been diagnosed as having previously had a stroke. The stroke may have been a recent event, such an event having initiated the process of the individual seeking clinical help. The terms “subject” and “patient” may be used interchangeably herein and refer to a mammal including a non-primate (e.g. a cow, pig, horse, dog, cat, rat and mouse) and a primate (e.g. a monkey and human). Preferably the subject or patient is a human. As used herein, the term ‘biomarker’ refers to a molecule present in a biological sample obtained from a patient, the concentration of which in said sample may be indicative of a pathological state. GFAP derivatives and total GFAP may be used as complementary biomarkers to other stroke biomarkers to increase the diagnostic power of a stroke assay. As used herein, the term ‘complementary biomarker’ refers to a biomarker that can be used in conjunction with other stroke biomarkers to support diagnosis; thus GFAP derivatives and GFAP parent with one or more stroke biomarkers are contemplated for use in stroke diagnosis. It is well understood in the art that biomarker normal or ‘background’ concentrations may exhibit slight variation due to, for example, age, gender or ethnic/geographical genotypes. As a result, the cut-off value used in the methods of the invention may also slightly vary due to optimization depending upon the target patient/population. The biological sample obtained from a patient is preferably a blood, serum or plasma sample. As used herein, the term ‘ex vivo’ has its usual meaning in the art and refers to a sample that has been removed from a patient's body. When a blood sample is taken from the patient for analysis, whole blood, serum or plasma is analysed. Analysis of the blood sample can be by way of several analytical methodologies such as mass spectrometry linked to a pre-separation step such as chromatography. The preferred methodology is based on immuno-detection. Immuno-detection technology is also readily incorporated into transportable or hand-held devices for use outside of the clinical environment. A quantitative immunoassay such as a Western blot or ELISA can be used to detect the amount of protein. A preferred method of analysis comprises using a multi-analyte biochip which enables several proteins to be detected and quantified simultaneously. 2D gel electrophoresis is also a technique that can be used for multi-analyte analysis. Although polyclonal or monoclonal antibodies are the preferred binding agents used in the invention, short chain antibody fragments, single chain fragments and other antibody-based probes may be used. Preferably, the solid-state device used in the methods of the present invention is a microtitre plate, preferably the Biochip Array Technology system (BAT) (available from Randox Laboratories Limited). More preferably, the Evidence Evolution, Evidence Investigator and Evidence Multistat apparatus (available from Randox Laboratories) may be used to determine the levels of biomarkers in the sample.
Glial Fibrillary Acidic Protein.
GFAP is a class-III intermediate filament (IF) protein localised to CNS astrocyte cells, gastrointestinal Schwann cells, enteric glial cells and retinal Muller cells. Approximately ten GFAP isoforms have been identified however most clinical research remains focused on isoform 1 which is the predominant GFAP expressed in CNS astrocyte cells. It is increasingly evident that GFAP is subject to complex patterns of PTM which defines its physiological function and role in pathological progression. A pivotal physiological parameter, phosphorylation, constitutes a key PTM event that defines transition between phosphorylated monomeric and dimeric unphosphorylated GFAPs that integrate with other proteins to generate a stable cellular cytoskeletal structure. In contrast, GFAP hyper-phosphorylation has been implicated in disease progression driving a loss of cellular integrity. A defining parameter of acute brain pathophysiology results in increased intracellular calcium sequestration and a shift in ionic balance which is excitotoxic, activating a number of damaging intracellular cascades, including lipid peroxidation and free-radical generation. Since citrullination or deamination is a calcium-dependent transformation of arginine residues performed by members of the peptidyl-arginine deiminases family it has been proposed to play a causative role in multiple neurodegenerative disorders. Additionally, protein citrullination is well documented as a defining parameter in autoimmune disease and GFAP autoantibodies are characteristic in the systemic circulation of stroke and TBI patients. Citrullinated GFAP has also been observed in neurodegenerative pathologies such as Alzheimer's brain tissue, while a complex profile of citrullinated GFAP has been detected in the brains of multiple sclerosis patients. Increased citrullination has also been detected in the retinae and optic cups of age-related macular degeneration and in glaucomatous optic nerves. Protein carbonylation is a modification indicative of oxidative stress that is characterised by the addition of carbonyl groups into protein-bound amino acids. Protein carbonylation can occur by direct oxidation of amino acid targets by reactive oxygen species or via interaction with reactive carbonyl species which are the product of lipid peroxidation. By either mechanism, the resulting carbonyl modifications can disrupt protein function and contribute to pathology. As a consequence, carbonylation is a metric of oxidative stress that is characteristic of various neurodegenerative pathologies, including multiple sclerosis and Alzheimer's disease. GFAP has been identified as a protein target subject to selective carbonylation. Glycosylation is one of the most common and a complex PTM events. Analysis of Alzheimer's disease tissues identified 46 soluble GFAP species. A 60% increase in the amount of more acidic GFAP species has been observed in AD the variants being both phosphorylated and N-glycosylated; more basic species were 0-glycosylated and exhibited no quantitative differences between post-mortem AD and control brains. This data provides clinical evidence that the characterisation of species-specific levels of proteins in pathophysiological conditions can improve clinical diagnostics.
Analytical Format for GFAP Detection/Quantification.
Each of the described methods of the invention can be effected using any suitable analytical technique but GFAP species are especially amenable to detection and quantification using mass spectrometry (preferably with in conjunction with a suitable chromatographic or gel based separation method, or the like) and immuno-based based methodologies; immunoanalytical methods are particularly preferred. The methods, as previously stated, preferably are based on the sandwich immunoassay format which involves a capture antibody and a detector antibody, each antibody binding to a different epitope on the target GFAP species. The capture antibody is preferably located at or chemically attached to the surface of a solid-state device. Typically, a sandwich immunoassay proceeds by way of firstly addition of the sample to be analysed, followed by addition of the detector antibody following capture antibody-analyte (GFAP species) binding. The detector antibody is conjugated to a detectable label which promotes or provides a detectable and measurable signal enabling the analyte to be detected or quantified. The signal can be any suitable electromagnetic radiation based on for example phosphorescence, fluorescence, chemiluminescence etc. Preferably, fluorescence or chemiluminescence is used. A particularly preferred detectable label is horseradish peroxidase. In a preferred immunoassay format a capture antibody of the invention is adsorbed or chemically attached to a solid state device, and after sample addition a detector antibody is added which binds to the captured GFAP species.
Statistical Analysis.
Cut-off concentrations or values are usually derived using standard statistical techniques. A common method of biomarker statistical analysis is to use univariate methods to compare biomarker levels in various groups and highlight those biomarkers whose concentrations significantly differ across and between particular groups. This is followed by Receiver Operator Characteristic (ROC) analysis. The ROC curve is a preferred method of assessing a diagnostic test's accuracy; it addresses both the sensitivity, the number of true positives, and the specificity, the number of false positives, of the test. If two or more biomarkers are to be used in the IS diagnostic method i.e. GFAP and one or more biomarkers including DNA, RNA and protein based markers, a suitable mathematical model, such as logistic regression equation, can be derived. The logistic regression equation might include other variables such as age and gender of patient. The ROC curve can be used to assess the accuracy of the logistic regression model. The logistic regression equation can be used independently or in an algorithm to aid clinical decision making. The skilled person will be aware of numerous suitable methods for developing statistical algorithms, and all of these are within the scope of the present invention. Examples of suitable classification algorithms include multinominal logistic regression, multilayer perceptron neural network (MLP), artificial neural networks, support vector machines and random forest classifiers. To acquire a defined sensitivity and specificity the two conditions non-pernicious stroke and pernicious stroke must be demarcated using a suitable metric and this requires a reference value to be acquired for the ‘normal condition’ (derived from the control population), in this case the non-pernicious cohort. The normal condition could also be a healthy cohort. The reference value could be a pre-defined cut-off value which achieves the optimal sensitivity and specificity values for the target condition, a median value, mean value, quartile value etc. The methodology and analyzer used to measure a biomarker in a biological sample inevitably results in the concentration value of a particular biomarker varying. Thus, although the cut-off value, mean value etc used to determine risk of a non-pernicious or pernicious condition in a suspected stroke patient will probably vary slightly from platform to platform e.g. for an immunoassay slight variation due to, for example, the antibody (monoclonal, polyclonal etc.) or substrate (bead, elisa plate, biochip etc.), the approach using the concentration level of GFAP as a biomarker for this purpose is valid and independent of the platform and methodology used in the analytical process.
The current findings also enable a method of predicting pernicious stroke (
Patient Group.
The study consisted of 39 patients displaying stroke symptoms admitted to the Emergency Department of KAT General Hospital, Athens, Greece. Patients were classified on admission using clinical analysis incorporating the Scandinavian stroke scale and by CAT scan. Blood samples were taken at the time of admission, at 24 hrs following admission, and every 24 hours thereafter up to day six except for patients who were diagnosed as TIA and stroke mimics who were subject to a single blood sample draw on admission. The time from the onset of stroke symptoms and hospital admission was <6 hours. Exclusion criteria included patients who were admitted to hospital >6 hours from the time of onset of stroke symptoms, patients with hepatic or renal pathologies and patients who had previously experienced a stroke. Samples from the CSF of individuals who had undergone sub arachnoid haemorrhage were also obtained and analysed using 1D gel electrophoresis and Western Blot.
Sample Analysis.
EDTA plasma samples of blood obtained from the patients of the study group was tested for GFAP. The proteins were detected and quantified using biochips incorporating GFAP-specific antibodies (4A11 capture antibody and GA-5 detector antibody—Kit 1) and the Evidence Investigator (Randox Laboratories Ltd, Crumlin, UK). Kit 2 comprised monoclonal antibodies (properties described in the Description) spotted on a ceramic biochip (the ceramic biochip as used for Kit 1, and as described in EP0874242). Samples from the CSF of individuals who had undergone sub arachnoid haemorrhage were analysed using 1D gel electrophoresis and Western Blot.
SDS Polyacrylamide Gel Electrophoresis and Western Blot.
Standard conditions were generally applied. Polyacrylamide gel (14%) was used. Samples were vortexed and incubated in a dry bath for 10-15 mins at 95° C. for approximately 10-15 minutes, followed by further vortexing. Samples and MW ladder (Thermo Scientific cat. 26616) were added to appropriate lanes and the gel run at approximately 120-200V until the dye front reached the top of the gel. The Western sandwich cassette was made up of white-sponge-filter-membrane-gel-filter-sponge black. The Western was run at approximately 120V for one hour with ice pack inside mini protean and left on a stir. The blot was then blocked in 5% milk powder (20 ml) for at least 30 minutes. Antibodies were added to the appropriate blots and washed with TBST (×3) for 10 minutes. If required anti-species HRP was added to the blots followed by further TBST (×4) washing. The membrane was developed using X-ray film, BM chemiluminescence Western blotting kit, developer and fixer. The use of gel data (see
Antibody Production.
Standard techniques were implemented for monoclonal antibody production for Kit 2. Sheep were immunized with Glial Fibrillary Acidic Protein from human Brain. Lymphocytes were collected and fused with heteromyeloma cells. Supernatants from the resulting hybridoma were screened for the presence of specific antibody using ELISA based assays. Positive hybridoma were cloned to produce stable monoclonal hybridoma. The antibodies were purified and evaluated by direct binding ELISA to determine their specificity for GFAP from human brain. Further molecular work was carried out using standard antibody characterisation ELISA and SDS and Western techniques. Two antibodies were identified for further testing, antibodies GF9 and GF10 (Randox Laboratories, Crumlin, Northern Ireland).
Antibody Characterisation.
Antibody binding characterisation was effected. BSA conjugated peptides spanning amino acid residues of GFAP were generated. Individual BSA conjugated peptides were immobilised at discrete test regions (DTRs) on a Biochip, as well as control substances. The two capture and two detector antibodies from Kits 1 & 2 were conjugated to horseradish peroxidase (HRP) and each individual conjugated antibody was incubated on an individual biochip and images obtained. The test substance fragments were spotted as outlined in
Results
Pernicious and non-pernicious stroke cohorts were compared using ROC curve analysis. The results are shown in Table 2 and
GFAP Kits 1 & 2 use different antibodies and differ in their sensitivities (
| Number | Date | Country | Kind |
|---|---|---|---|
| 1619820.2 | Nov 2016 | GB | national |
| 1621964.4 | Dec 2016 | GB | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2017/080247 | 11/23/2017 | WO | 00 |
